The Archive · 3 posts
Transforming precision medicine! 🌟 GENinCode (GENI) leads in genetic testing innovation, empowering healthcare & improving lives. 🧬
GENinCode reports 14% revenue growth and advances US FDA CARDIO inCode submission. But losses widen, cash low – still high risk. Read more.
June 8, 2026
Showing 2 of 3 posts
GENinCode posts 15% H1 revenue growth to £1.6m, advances FDA De Novo pathway, and eyes US/EU distribution deals. Steady progress for the genetic diagnostics firm.
JoshuaAugust 26, 2025
GENinCode FY24: 25% revenue growth to £2.7m, losses narrow. Progress towards profitability as commercial momentum builds across NHS, EU and US markets.
JoshuaJune 4, 2025